The UK‘s National Health Service (NHS) is pioneering a groundbreaking approach to cancer treatment by offering an innovative under-the-skin injection for cancer patients in England.
This treatment, atezolizumab (also known as Tecentriq), was granted approval by the Medicines and Healthcare products Regulatory Agency (MHRA).
Unlike the traditional intravenous infusion method, which can take up to an hour and be challenging for some patients, this new injection takes just seven minutes.
This streamlined approach is expected to reduce treatment times by up to three-quarters, significantly enhancing the efficiency of cancer care.
Atezolizumab is an immunotherapy drug, manufactured by Genentech (a Roche company), that stimulates the patient’s immune system to identify and combat cancer cells.
Currently administered via transfusion, this treatment is available for patients with various cancers, such as lung, breast, liver, and bladder cancers.
The NHS anticipates that the majority of the approximately 3,600 patients starting atezolizumab treatment each year in England will transition to this time-saving injection. This innovation not only promises faster and more convenient care but also enables healthcare teams to treat more patients throughout the day.
The Hubli Express News is on WhatsApp, you can join the group by clicking the link below to get latest information from local to global.